Abstract
Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p < 0.001) and 53% of adenomas (p < 0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.
Original language | English (US) |
---|---|
Pages (from-to) | 141-150 |
Number of pages | 10 |
Journal | International Journal of Pancreatology |
Volume | 29 |
Issue number | 3 |
DOIs | |
State | Published - 2001 |
Keywords
- Colorectal cancer
- Immunostaining
- Intraductal papillary mucinous neoplasms
- Monoclonal antibody
- Pancreatic ductal cancer
- Severely dysplastic adenomatous colonic polyps
ASJC Scopus subject areas
- Oncology
- Endocrinology
- Gastroenterology